Merck’s WINREVAIR shows promise in phase 2 study for hard-to-treat pulmonary hypertension

The drug is being tested for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction

Merck’s two-drug HIV regimen hits phase 3 success

The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks

Piramal Pharma Solutions’ UK facility bags updated MHRA GMP certification

Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub

Siolta Therapeutics’ novel microbiome therapy shows promise in preventing allergic diseases in infants

Sudeep Pharma eyes Rs. 895 crore fundraising from debut on bourses

The issue comprises a fresh issue of Rs. 95 crore and targeting a total raise of around Rs. 895 crore

Cardiol Therapeutics wins US patent protection for heart-disease drug platform

The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38

Briefs: Zydus, Divi's Laboratories and Relonchem

FDA closes inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad with 2 observations

Lupin launches long-acting Risperidone in US

This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology

Indian pharma sector poised for a global leap beyond generics: K. Raja Bhanu, DG, PHARMEXCIL

With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards

Merck to acquire Cidara Therapeutics for $9.2 billion

Diversifying its portfolio to include late-phase antiviral agent